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Abstract  (232 words) 
Cyclopropylamines, inhibitors of monoamine oxidases (MAO) and lysine-specific demethylase 
(LSD1), provide a useful structural scaffold for the design of mechanism-based inhibitors for the 
therapy of depression and cancer. For new compounds with the less common cis relationship and 
with an alkoxy substituent at the 2-position of the cyclopropyl ring, the apparent affinity from 
docking revealed little difference between the enantiomers. Using the racemate, kinetic parameters 
for the reversible and irreversible inhibition of MAO were determined. No inhibition of LSD1 was 
observed. The reversible inhibition of MAO A gave high IC50 values for most compounds but sub-
micromolar values with MAO B. After pre-incubation with the enzyme, the inhibition was 
irreversible in both MAO A and MAO B and the activity was not restored by dilution. Spectral 
changes during inactivation of MAO A showed bleaching at 456 nm and an increase at 400 nm, 
consistent with flavin modification. These derivatives are MAO B-selective mechanism-based 
inhibitors without inhibition of LSD1. The best inhibitor was cis-N-benzyl-2-
methoxycyclopropylamine, with an IC50 of 5 nM for MAO B and 170 nM for MAO A after 30 min 
preincubation. This cis-cyclopropylamine is over 20-fold more effective than tranylcypromine so 
could be studied as a lead for selective inhibitors of MAO B that do not inhibit LSD1. 
 
Abbreviations 
MAO, monoamine oxidase; TCP, tranylcypromine; LSD1, histone demethylase (also known as 
KDM1A)  
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Introduction 
Interest in cyclopropylamine chemistry was revived when tranylcypromine (TCP; trans-2-
phenylcyclopropan-1-amine) was identified as an irreversible inhibitor of LSD1, one of the key 
demethylase enzymes in epigenetic gene regulation [1, 2]. TCP is a mechanism-based inactivator of 
monoamine oxidases (MAO) and has been used in the treatment of depression for decades [3-5]. 
TCP inactivates MAO B by forming the C4a adduct with the flavin cofactor whereas LSD1 forms 
the N5 adduct [5, 6]. These adducts are formed after the oxidation of tranylcypromine by the 
enzyme, and each may arise via a C4a-N5 cyclic structure [6-8]. A new series of 1-substituted 
cyclopropylamine derivatives with improved affinity for LSD1 formed different adducts depending 
on the derivative, at C4a, N5, or bridging both, probably via a radical mechanism [9]. The 
inactivation is irreversible so new protein synthesis is required for the restoration of activity in the 
cell. 
The potential usefulness of cyclopropylamine inhibitors of MAO and LSD1 for the therapy of 
depression [10-12] and cancer [4, 13-17], and the need for selective inhibition of the targets has 
prompted the synthesis and evaluation of new inhibitors such as trans 1-substituted derivatives [9]. 
For the MAO enzymes, more derivatives of trans-isomers have been studied, but cis-2-
phenylcyclopropylamine is only slightly less effective than the trans-isomer [18-20].  Enantiomeric 
selectivity is also a concern. On MAO B, the 1R,2S-(-)-TCP was 20-fold more effective as a 
competitive inhibitor, but cis-2-phenylcyclopropylamine showed no enantiomeric selectivity [4, 5, 
21]. LSD1 showed no enantiomeric selectivity for TCP [5, 22], but the two enantiomers of a 1-
substituted cyclopropylamine gave different adducts [9].  
Here we report the inhibition of  the two forms of MAO by selected cis-isomers of primary and 
secondary cyclopropylamines with an alkoxy group at the 2-position of the cyclopropyl ring 
replacing the more common phenyl substitution [23]. The trans-compound TCP, already well-
established as a drug before the full impact of two forms of MAO was appreciated [21, 24, 25], is 
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included as a reference compound.  We show that cis-cyclopropylamine, like TCP, forms a covalent 
adduct with the flavin in MAO A and MAO B. Docking studies, performed to explore enantiomer 
binding in MAO A and MAO B, also revealed occupancy of the imidazoline (I2) site [26-28] in the 
entrance cavity of MAO B.  
TABLE 1 HERE 
Results  
No inhibition of LSD1 
The cis-cyclopropylamine compounds, synthesised as before [23], were tested against LSD1 for 
which TCP is an established lead. In the LSD1 enzyme assay, the compounds were inactive at the 
maximum tested concentration of 25 µM. 
Molecular modelling with MAO to explore enantiomeric selectivity 
Reversible binding can be predicted by docking, so this was used to guide the selection of 
previously synthesised compounds [23] used in this study and then to explore whether the 
enantiomers might bind differently to MAO A and MAO B (Table 1).  Molecular modelling [29] 
was performed to determine binding energies and estimated Ki values for the cis-cyclopropylamines 
with MAO A and MAO B (Supplementary Table S1).  Theoretical Ki values for both enantiomers 
of all seven compounds were obtained by docking the compounds into MAO A (2Z5X) and MAO 
B (2V5Z) using Autodock [30] (as shown in Table 1) and Vina [31]. Both programmes gave 
concordant values for the binding energies with essentially no difference between the (1R,2S) and 
(1S,2R) enantiomers (Supplemental Table S1). The aromatic group improves binding energy, and 
the para-methyl group makes compounds 3 and 6 better than 4 in this theoretical ranking. The para-
chloro compound 7 gives values similar to the para-methyl one.   
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Based on the lack of enantiomeric differences, racemic cis-cyclopropylamines were used for the 
experimental work. 
Reversible binding: Experimental IC50 values  
For MAO A and B, the reversible interaction was measured as IC50. Under the conditions of the 
assay used here, the IC50 values with MAO A are proportional to Ki and reflect the initial 
reversible binding of the inhibitor to MAO A [32]. For MAO B, the IC50 is influenced by the 
oxidative half-reaction as well as the reductive half reaction because the rates of reduction and 
reoxidation of the flavin in the steady state are similar. In practice, the affinity of the inhibitor for 
the reduced form of MAO B becomes significant, so that the experimental IC50 is influenced by 
more factors than is the true Ki for binding to a single (oxidised) form of MAO B [32]. The 
reversible inhibition of MAO A by these cis-cyclopropylamine compounds is very poor as indicated 
by the high IC50 values for all compounds except 4 (Table 1). In contrast, the IC50 values are around 
micromolar for compounds 1, 2, 4, and 5 with MAO B (Table 1), demonstrating that the selectivity 
of reversible binding for MAO B is as good as (for 3, 6, 7), or better than the standard drug, TCP 
(for 1, 2, 4, 5).  
 The Ki values obtained from docking calculations should predict at least qualitatively the 
experimental values for reversible binding for MAO A in these assays that were carefully designed 
to reflect the initial reversible binding to the active site. With the exception of compound 4, the 
calculated Ki values for MAO A from Autodock shown in Table 1 agree with the order of potency 
observed in the experimental IC50 values. In contrast, for MAO B compounds 3, 6 and 7 give poor 
experimental IC50 values, compared to the predicted affinity (Table 1), presumably for the kinetic 
reasons explained above. In general, the output from Autodock predicted a selectivity for MAO B 
over MAO A much smaller than found experimentally. 
TABLE 2 HERE 
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IC50 values for irreversible binding 
All compounds showed a time-dependent increase in inhibition (decreased IC50) due to irreversible 
inactivation, as demonstrated by the lack of restoration of activity after dilution. Table 2 gives the 
IC50 values after a 30 min preincubation of the inhibitor with the enzyme. 
The selectivity ratios calculated from the 30 min IC50 values indicate that 6 and 7 act equally on 
MAO A and B. The other compounds (1-5) are better inactivators of MAO B than of MAO A and, 
thus, are more selective than TCP (Table 2). The most effective inactivator is N-benzyl-2-
methoxycyclopropylamine (4) with an IC50 of 5 nM against MAO B, 15–fold more potent than TCP 
and 10-fold more selective for MAO B. Comparing the selectivity at 0 and 30 min, compounds 1, 2, 
5, 6 and 7 do not change, but compound 3 is more selective at 30 min whereas 4 has a lower 
selectivity for MAO B at 30 min. Compounds that give unchanged, more, and less selectivity (1, 3, 
4, 6) were studied in detail to investigate whether the rate constant for inactivation (kinact) could 
account for the differences. 
TABLE 3 HERE 
Kinetic parameters for inactivation of MAO A and MAO B by cis-cyclopropylamines 
After pre-incubation with the enzyme, the inhibition by all four selected compounds (1, 3, 4, 6) was 
irreversible and the activity was not restored by dilution into excess substrate. The kinetic 
parameters for the mechanism-based irreversible inactivation of MAO A, termed KI and kinact [33], 
were determined from the time course of inactivation and are presented in Table 3. The MAO A 
irreversible KI values are all poor, with the exception of 4 (Table 3). The KI values for MAO B 
indicate much more discrimination of the structural variations in the compounds: 4 (0.07 µM) < 1 
(0.9 µM) < 3 (5 µM) < 6 (17 µM), presumably as a result of its narrower substrate cavity [34].  
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 For MAO A, 2-methoxy-2-methylcyclopropylamine (1) gives the fastest rate of inactivation (kinact = 
0.17 min-1), perhaps because its small size facilitates the correct orientation for its oxidation. 
Compounds 3, 4, and 6 all inactivate MAO A at slower rates. Both 4 and 1 inactivate MAO A 
without generation of detectable H2O2. For MAO B, 1 gives the slowest inactivation (kinact = 0.016 
min-1), whereas 4 gives the fastest (kinact = 0.104 min-1), but both generate H2O2 during the 
preincubation with MAO B, indicating less tight coupling between oxidation and adduct formation.  
The specificity constants (kinact/KI) provide a comparison of the efficiency of inactivation by each 
compound, and from them, the selectivity for MAO B compared to MAO A is calculated as a ratio 
(last column of Table 3). The specificity constants for inactivation show that all compounds 
inactivate MAO B more efficiently than MAO A. Compared to TCP, compound 4 more effectively 
inactivates MAO A (4 times better) and MAO B (> 20 times better). Compound 4 is also 5 times 
more selective for MAO B. The rate of inactivation (kinact) by compound 4 is considerably lower 
than that by TCP (15-fold in MAO A and > 2-fold in MAO B) but the low KI values for 4, 
particularly for MAO B (65 nM) offset the lower rates. 
FIGURE 1 HERE 
Characterization of the adduct formed between MAO A and 4 
Covalent adducts with the N5 group of the FAD moiety of MAO, such as formed after inactivation 
by clorgyline or deprenyl, are characterised by a distinctive change in the spectrum of MAO that 
differs from that seen for the C4a adduct [35-38]. The spectral changes that occur during adduct 
formation with cis-cyclopropylamines  4 were studied (Fig. 1). The MAO A flavin absorbance at 
456 nm was bleached indicating at least partial reduction of the flavin (Fig. 1A). The absorbance at 
400 nm increased but this increase lagged behind the rapid flavin reduction as seen in the time 
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course (Fig. 1B) and in the difference spectra in Fig. 1C. This suggests a slower chemical step for 
adduct formation after the reduction of the flavin. 
The spectral change during inactivation of MAO A by compound 4 has some similarity to that for 
N5 modification by clorgyline, but it has a less intense absorbance increase at 400 nm rather than 
the large 415 nm increase seen for N5 propargyl adducts with MAO A. However, the flavin remains 
reduced after denaturation with urea, suggesting that it is a stable adduct, unlike the labile adducts 
for trans-cyclopropylamines assumed to be at C4a [39] where reoxidation of the flavin is obvious 
after urea denaturation. 
FIGURE 2 HERE 
Small cis-cyclopropylamines can occupy multiple positions in the active sites 
With the exception of 4, all the cis-cyclopropylamines are poor inactivators of MAO compared to 
TCP. Molecular modelling was used to compare how these small molecules interacted with the 
active sites of the two enzymes. Multiple poses were found for each compound at various 
locations in the active site and with varying orientations, as illustrated for selected 
enantiomers in Fig. 2. Interestingly, in MAO B, poses with energy minima for the smallest 
compound 1 are found in the entrance cavity, in mid-cavity, and near the flavin. The latter location 
(as shown in Fig. 2, top) near the N5 of the flavin is required in order to inactivate MAO B.  The 
amino acids surrounding the (1R,2S)- enantiomer of compound 1 near the flavin are shown in Fig. 3 
(left). The entrance cavity pose (Fig. 3, right) was found in only two of the ten Autodock runs for 
(1R,2S)-1 and gave an energy of -3.74 kcal mol-1, and in only one run for (1S,2R)-1 with an energy 
of -4.33 kcal mol-1. This entrance cavity location (Fig. 3) is similar to that of 2-BFI bound in the 
imidazoline I2 site of MAO B that has been characterised in binding studies and demonstrated by 
crystallography [26, 27]. However, unlike the I2 ligands that have nM affinity, the predicted Ki for 
binding of compound 1 at this location is in the micromolar range. 
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The low probability of binding close to the flavin may also explain the low rate of inactivation 
(Table 3:  kinact is 0.016 min-1 for 1 with MAO B compared to 0.263 min-1 for TCP). The 
introduction of a benzyl substituent at the nitrogen improves the affinity for MAO A but not for 
MAO B, and increases the rate of inactivation (0.016 min-1 for 1 to 0.104 min-1 for 4) for MAO B 
but not for MAO A (Table 3).  
FIGURE 3 HERE 
Discussion 
 
The inhibition of MAOs by cyclopropylamines is well established, and is exemplified by the 
clinical drug tranylcypromine (TCP). In TCP, the cyclopropylamine bears a trans relationship. The 
phenyl substituent is considered to facilitate ring opening of the cyclopropyl ring by stabilizing 
radical-type intermediates [41]. This has led to considerable interest in trans-substituted 
tranylcypromine analogues as MAO inhibitors as well as inhibitors of the recently identified 
epigenetic enzyme LSD1. Here, we have investigated novel cyclopropylamines with the less 
common cis relationship. Furthermore, our compounds do not contain a phenyl ring as 
cyclopropane substituent but instead have an intervening alkoxy group. These new 
cyclopropylamine derivatives were found to be inactive against LSD1 at concentrations of 25 µM. 
For MAO, although the initial binding is micromolar, these cis-cyclopropylamines inhibit MAO A 
and MAO B irreversibly at submicromolar levels, making them selective for MAO without an 
effect on LSD1. The best inhibition was observed with MAO B. Compound 4 is >20 times more 
effective than TCP, so this di-substituted cyclopropylamine (secondary amine) could be studied as a 
lead for selective inhibitors of MAO B that do not inhibit LSD1. 
Both the primary (1, 2) and the secondary (3-7) amines can inactivate both MAO isoenzymes, 
confirming that cis-cyclopropylamines interact with MAO to form reactive products that can form a 
covalent bond to the flavin. The spectrum with MAO A during inactivation and the stability of the 
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adduct formed during unfolding suggest that the modification by N-benzyl-2-methoxycyclo-
propylamine 4 may be at the N5 of the flavin. Although the crystal structure of MAO B after TCP 
inactivation shows C4a modification, the structure of LSD1 shows that TCP modifies the N5 of the 
flavin [5]. Recent crystal structures have revealed that some 1-substituted cyclopropylamines 
formed different adducts with LSD1 at C4a, N5, or bridging both, probably via a radical mechanism 
[9]. Others have also reported formation of a cyclic N5 and C4a adduct [6-8, 13, 22, 42, 43], so 
perhaps both are possible even if only one form crystallizes. The spectrum of the adduct is not 
definitively that of an N5 adduct such as formed with clorgyline or deprenyl [35, 44], so only the 
stability [39] favours that interpretation for this cis-cyclopropylamine. This work does not address 
the structure of the adduct nor the mechanism of adduct formation but the lack of H2O2 production 
during inactivation of MAO A means that a radical mechanism proposed by others must be 
considered [9, 45]. 
 
Conclusion 
 
cis-N-Benzyl-2-methoxycyclopropylamine (4) is a new irreversible MAOI with IC50 5 nM for MAO 
B, 170 nM for MAO A, and no activity on LSD1. 
 
Experimental procedures 
Compounds 
The cis-isomers of primary and secondary cyclopropylamines with an alkoxy group at the 2-
position of the cyclopropyl ring replacing the more common phenyl substitution were synthesized 
as previously described [23]. 
Page 10 of 25FEBS Journal
Enzyme activity 
Initial activity for membrane-bound MAO (Sigma-Aldrich, UK) was determined from the 
production of hydrogen peroxide, coupled to a dye via horseradish peroxidase producing the 
fluorescent resorufin [46-48]. For the reversible inhibition, IC50 values were determined from the 
rates with varied inhibitor concentrations in the presence of 2.5 x KM substrate concentration with 
the enzyme added last. Under the conditions used, the KM for tyramine with MAO A was 0.4 mM 
and for MAO B was 0.16 mM. The rates were analysed in Graphpad PRISM v4. 
The IC50 values for the irreversible inactivation of MAO A and MAO B were determined from the 
activity (assayed as above) remaining after 30 min of incubation of the enzyme and inhibitor. 
Inactivation parameters (KI and kinact) were determined as in [33, 38]. Data are expressed as value ± 
standard deviation (SD) obtained by fitting the data (at least 20 points) to the appropriate three-
parameter equation using GraphPad PRISM 4.  At least two separate determinations were made for 
each value reported.  
Molecular Docking 
Molecular models of the cis-cyclopropylamine inhibitors were built and optimised using ArgusLab 
4.0.1 on an Intel i7 HP Laptop, operating Windows 8 Home Premium. MAO A (PDB code: 2Z5X) 
and MAO B (PDB code: 2V5Z) protein structures were minimised using Accelrys 6.0 adopting a 
CHARMM force field and simulated annealing. All .pdbqt, .gpf ,and .dpf files where created using 
AutoDock tools software, adopting a Lamarckian genetic algorithm and converted to .glg and .dlg 
files using the AutoGrid4 and AutoDock4 coding sequences, respectively. Docking was achieved 
using AutoDock4 and Vina coding scripts. All comparisons were carried out using PyMOL. 
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 Table 1.  Experimental IC50 values and predicted Ki values for reversible inhibition of MAO 
by cis-cyclopropylamines 
  
Compound 
 
Experimental 
(racemic) 
IC50 (µM) 
Selectivity 
IC50 MAOA 
IC50MAOB 
Autodock  
(1S,2R)  
Ki (µM) 
 MAO A MAO B  MAO A MAO B 
 
1             
 
>300 3.70 >81 2010 674 
2        
>300 0.78 >385 691 445 
3           
52.4 24.5 2.1 4.65 2.88 
4             
 
21.1 0.17 124 89.0 48.8 
5          
 
>400 4.61 >87 61.7 14.4 
6           
115 64.0 1.8 17.4 7.81 
7         
71.3 33.4 2.1 16.0 6.37 
Tranylcypromine 23.6 4.02 5.9 91.0 105 
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Table 2. Irreversible inhibition of MAO after 30 min. 
 
Compound 
(racemic) 
 
IC50 (µM)* IC50 MAOA IC50MAOB 
MAO A MAO B Selectivity 
1             6.12 ±0.03 0.084 ±0.05 73 
2  21.6 ± 0.5 0.029 ±0.002 745 
3         10.8 ±5.0 0.104 ±0.017 104 
4          0.175 ±0.068 0.00470 ± 0.00005 37 
5          3.00 ±0.30 0.120 ± 0.004 25 
6        2.55 ±0.22 3.03 ±0.20 0.8 
7       1.75 ±0.20 1.49 ±0.22 1.1 
Tranylcypromine 0.237 ±0.061 0.0735 ±0.0049 3.2 
Clorgyline 0.00039 0.013 0.03 
Deprenyl 0.635 0.00029 2190 
* IC50 values ±sd from the three-parameter fit to at least 20 experimental values.
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Table 3. Parameters for inactivation by TCP and by 2-substituted cis-analog
 MAO A  MAO B  Selectivity for MAO B 
Compound 
KI  
(µM) 
kinact  
(min-1) 
kinact /KI 
(min. mM -1) 
 
KI  
(µM) 
kinact  
(min-1) 
kinact /KI 
(min. mM -1) 
 MAO B kinact /KI 
MAO A kinact /KI 
1 58.9 ±7.4 0.167  ±0.010 2.84  0.90 ±0.18  0.016 ±0.001 18  6.33 
3 30.4 ±9.5 0.028  ±0.003 0.92  4.5 ±0.6 0.037 ±0.002 8.22  8.93 
4 0.123 ±0.051 0.052  ±0.012 440  0.065 ±0.012 0.104 ±0.005 1600  3.64 
6 16.6 ±3.2 0.030  ±0.003 1.81  17.5 ±5.6 0.058 ±0.007 3.31  1.83 
TCP 7.7 ±1.0 0.776  ±0.034 101  3.8   ±0.6 0.263 ±0.005 69  0.68 
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Figure Legends 
 
Fig. 1.  MAO A inactivation by 4: spectral change during adduct formation.  
The original spectra (left) and the time course (middle) show rapid reduction of MAO A (18 µM) 
flavin by compound 4 (20 µM). Adduct formation at 400 nm proceeds more slowly than reduction 
of the flavin at 456 nm as shown in the time course (middle) and the difference spectra (right, where 
the spectrum for MAO A alone has been subtracted from the MAO A+4 mixture). The incubation 
shown resulted in about 90% inactivation; a second addition of compound 4 was required for 
complete inactivation. 
 
Fig. 2.  Docking poses for cis-cyclopropylamines in the active sites of MAO A and MAO B. 
Left: MAO A (PDB code 2Z5X); Right: MAO B (PDB code 2V5Z). Docking simulations were 
carried out using AutoDock4 (carbons in green) and Vina (carbons in white); visualisation was 
carried out using PyMOL. Compound 1 with MAO A (top, left) was 1R,2S, whereas for all the 
others, the enantiomer was 1S,2R. Optimum poses were defined by the steric position necessary for 
interaction between the flavin N5 and the inhibitor 
 
Fig. 3.  Amino acids surrounding (1R,2S)-1 either near the flavin or in the imidazoline I2 site 
of MAO B. 
Docking of compound 1 (carbons in green) to MAO B (2V5Z) was carried out using AutoDock (10 
runs).  Various poses were found: A - bound near the flavin (yellow); B - in 2 of 10 poses, near the 
I2 site within the entrance cavity. Hydrogen bonding interactions are shown as green dashes.  
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nm as shown in the time course (middle) and the difference spectra (right, where the spectrum for MAO A 
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60x20mm (600 x 600 DPI)  
 
 
Page 22 of 25FEBS Journal
  
 
 
Fig. 2.  Docking poses for <cis>-cyclopropylamines in the active sites of MAO A and MAO B.  
Left: MAO A (PDB code 2Z5X); Right: MAO B (PDB code 2V5Z). Docking simulations were carried out using 
AutoDock4 (carbons in green) and Vina (carbons in white); visualisation was carried out using PyMOL. 
Compound 1 with MAO A (top, left) was 1R,2S, whereas for all the others, the enantiomer was 1S,2R. 
Optimum poses were defined by the steric position necessary for interaction between the flavin N5 and the 
inhibitor.  
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Fig. 3.  Amino acids surrounding (1R,2S)-1 either near the flavin or in the imidazoline I2 site of MAO B.  
Docking of compound 1 (carbons in green) to MAO B (2V5Z) was carried out using AutoDock (10 
runs).  Various poses were found: A - bound near the flavin (yellow); B - in 2 of 10 poses, near the I2 site 
within the entrance cavity. Hydrogen bonding interactions are shown as green dashes.  
 
205x76mm (72 x 72 DPI)  
 
 
Page 24 of 25FEBS Journal
  
 
 
Graphical Abstract  
153x55mm (72 x 72 DPI)  
 
 
Page 25 of 25 FEBS Journal
 Supporting information 
 
 
 
cis-Cyclopropylamines as mechanism-based inhibitors of 
Monoamine Oxidases. 
Thomas Malcomson1, Kemal Yelekci2, Maria Teresa Borrello3, A. Ganesan3, Elena Semina4, 
Norbert De Kimpe4, Sven Mangelinckx4, and Rona R. Ramsay1*  
1Biomedical Sciences Research Complex, University of St Andrews, St Andrews, UK; 2Kadir Has 
University, Department of Bioinformatics and Genetics, Istanbul, Turkey; 3School of Pharmacy, 
University of East Anglia, Norwich, UK; 4Department of Sustainable Organic Chemistry and 
Technology, Ghent University, Ghent, Belgium.  
!
!
!
!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S1 footnote   
 
*Docking simulations (10 runs) used a 70x70x70 point grid centered on the N5 of the flavin. Final molecular 
conformations (poses) with the same energy were grouped into clusters. Predicted Ki values are for the highest 
populated cluster. 
!  
!
 
 Supplementary Table S1. Binding energy and predicted Ki * (See Table 1 for structures of compounds) 
   AutoDock Vina 
Enzyme Enantiomer Compound Clusters Poses in top 
Cluster 
Affinity    
(kcal mol-1) 
Predicted Ki 
(µM) 
Affinity    
(kcal mol-1) 
 
 
 
 
 
 
 
 
 
MAO A 
 
 
 
 
(1R,2S) 
1 2 4 -3.64 2000 -4.2 
2 4 2 -4.28 729.0 -4.8 
3 2 6 -6.24 19.61 -7.3 
4 2 6 -5.46 95.29 -6.4 
5 2 7 -5.74 58.13 -6.6 
6 2 9 -6.41 19.60 -7.3 
7 1 10 -6.61 13.28 -7.1 
 
 
 
 
(1S,2R) 
1 2 9 -3.64 2010 -4.2 
2 3 2 -4.30 691.3 -5.0 
3 1 10 -7.18 4.65 -7.2 
4 3 1 -5.53 88.97 -6.5 
5 1 10 -5.72 61.73 -6.5 
6 3 8 -6.19 17.41 -7.3 
7 3 2 -6.47 16.02 -6.8 
 
 
 
 
 
 
 
 
 
MAO B 
 
 
 
 
(1R,2S) 
1 2 8 -3.82 1500 -4.2 
2 5 3 -4.55 446.7 -5.5 
3 2 8 -7.32 2.79 -8.0 
4 2 9 -5.52 87.37 -6.9 
5 1 10 -6.69 12.23 -6.7 
6 4 7 -6.88 9.01 -7.5 
7 2 6 -6.73 7.79 -7.3 
 
 
 
 
(1S,2R) 
1 2 1 -4.33 674.2 -4.4 
2 2 1 -4.57 445.3 -5.6 
3 3 6 -7.55 2.88 -7.4 
4 3 8 -5.85 48.81 -6.9 
5 1 10 -6.43 14.39 -7.1 
6 3 1 -6.97 7.81 -7.5 
7 2 7 -7.09 6.37 -7.3 
